Cell line · CVCL_2235
Papers116
1 to 20 of 116
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Castration-resistant prostate cancer cells are addicted to the high activity of cyclin-dependent kinase 2. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Vitronectin Enrichment in Prostate Cancer Liver Metastases Promotes Adhesion and Survival. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| SPEN Inactivation Drives Resistance to Androgen Receptor Pathway Inhibitors in Metastatic Prostate Cancer. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A stress-adaptive lipid kinase axis defines metabolic vulnerabilities in neuroendocrine prostate cancer. | Cancer Cell | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Stress-Adaptive Lipid Kinase Axis Defines Metabolic Vulnerabilities in Neuroendocrine Prostate Cancer. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| 3beta-HSD1-mediated steroid back-conversion maintains androgen signaling in prostate cancer. | Mol Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer. | J Clin Invest | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Co-Targeting Nuclear Export and Translation Initiation Uncovers a Therapeutic Vulnerability in Lethal Prostate Cancer. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Evaluation of Tissue from Patients with Prostate Cancer Identifies B7-H3 as an Androgen-Regulated, Broadly Expressed, Combinatorial Therapeutic Target. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Quantification of Antibody-Drug Conjugate Targets in Head and Neck Squamous Cell Carcinoma. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Androgen Receptor-Induced Lactoferrin Accelerates Prostate Tumorigenesis Through Modulating Ferroptosis. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Phase Separation of NFIB Suppresses SLC3A2-Mediated Ferroptosis in Castration-Resistant Prostate Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Androgen Signaling Represses Homeobox C9, an Inhibitor of Androgen Receptor, in Prostate Cancer Cells. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Overexpression of the ERG oncogene in prostate cancer identifies candidates for PARP inhibitor-based radiosensitization. | J Clin Invest | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Lactate derived from cancer-associated fibroblasts promotes alternative splicing and castration resistance in prostate cancer. | Sci Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Landscape of Allele-Specific Expression in Prostate Cancer Reveals Recurrent, Stage-Specific Events in AR Signaling and Resistance Pathways. | Mol Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PM534, a Novel Colchicine Site Tubulin Inhibitor with Broad-Spectrum and Resistance-Overcoming Antitumor Activity. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Multiple ETS family transcription factors bind mutant p53 via distinct interaction regions. | FEBS Lett | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Serotonin Modulates Lineage Plasticity in Neuroendocrine Prostate Cancer via Epigenetic Reprogramming. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_2235/papers